TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Co-Infection
Study data from University of Turin update understanding of HIV/AIDS co-infection
October 21st, 2008
According to recent research published in the Journal of Infection, "Administration of rifampicin or rifabutin in the treatment of HIV-associated tuberculosis (TB) is made rather complex by the risk of drug-drug interactions with most antiretrovirals and/or for reasons of toxicity." "While in selecting the appropriate concomitant regimens the priority usually goes to rifamycins with exclusion of interacting antiretrovirals, in some circumstances the former cannot be used and anti-TB rifamycin-free regimens must be administered," wrote S. Bonora and colleagues, University of Turin. The researchers concluded: "We describe here the clinical...
Source: TB & Outbreaks Week (2008-10-21)
|
